Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. Its lead candidate, TTI 621, is a SIRPaFc fusion protein that consists of the CD47 binding domain of human SIRPa linked to the Fc region of a human immunoglobulin G1 (IgG1).
In order to optimize our website for you and to be able to continuously improve it, we use cookies. By continuing to use the website, you agree to the use of cookies. Further information on cookies can be found in our Privacy Policy.
